Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. 2005

Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.

Although the V3 loop of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) effectively elicits potent neutralizing antibody responses, the specificity of the antibody response is often restricted to T cell line adapted (TCLA) strains and a small subset of primary isolates, limiting its utility for an AIDS vaccine. In this study, we have compared Env immunogens with substituted V3 regions to combinations of strains from different clades and evaluated their ability to expand the breadth of the neutralizing antibody response. When the V3 region from HIV BaL was substituted for HIV HXB2, an effective neutralizing antibody response against several clade B primary isolates was elicited, but it remained restricted to neutralization of most clade B isolates. In an attempt to expand this response further, a linear epitope recognized by the broadly neutralizing 2F5 antibody was inserted into V3. A V3 2F5 epitope was identified that bound to 2F5 and elicited a potent 2F5 antibody response as an immunogen, but the antisera neutralized only a lab-adapted strain and not primary isolates. In contrast, combinations of Envs from clades A, B, and C, elicited neutralizing antibodies to a more diverse group of primary HIV-1 isolates. These studies suggest that combinations of Env immunogens, despite the limited reactivity of the V3 from each component, can be used to expand the breadth of the neutralizing antibody response.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016915 AIDS Vaccines Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced. AIDS Vaccine,HIV Vaccine,HIV Vaccines,Vaccine, AIDS,Vaccine, HIV

Related Publications

Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
November 2014, Journal of virology,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
December 2006, The Journal of infectious diseases,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
May 2007, Vaccine,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
October 2018, Cell reports,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
November 2017, Journal of virology,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
November 2007, Vaccine,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
July 1995, Nature medicine,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
April 2011, The Journal of infectious diseases,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
November 2015, Nature medicine,
Bimal K Chakrabarti, and Xu Ling, and Zhi-Yong Yang, and David C Montefiori, and Amos Panet, and Wing-Pui Kong, and Brent Welcher, and Mark K Louder, and John R Mascola, and Gary J Nabel
January 2018, PloS one,
Copied contents to your clipboard!